ENDO 2021 – Patient Worthy

rawpixel / Pixabay

Clinical Data on AZP-3601 for Hypoparathyroidism Presented at ENDO 2021

Post author:Jessica Lynn
Post published:March 25, 2021
Post category:Chronic Kidney Disease hypoparathyroidism

At the Endocrine Society's Annual Meeting, or ENDO 2021, Amolyt Pharma ("Amolyt") shared positive clinical data from a Phase 1 clinical trial evaluating AZP-3601 for patients with hypoparathyroidism. Although…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More